Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free KURA Stock Alerts

Kura Oncology (KURA) Financials

Kura Oncology logo
$9.22 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$9.22 +0.00 (+0.04%)
As of 07:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Kura Oncology

Annual Income Statements for Kura Oncology

This table shows Kura Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -28 -60 -63 -90 -130 -136 -153 -174 -279
Consolidated Net Income / (Loss)		 -23 -28 -60 -63 -90 -130 -136 -153 -174 -279
Net Income / (Loss) Continuing Operations		 -23 -28 -60 -63 -90 -130 -136 -153 -174 -279
Total Pre-Tax Income 		-23 -28 -60 -63 -90 -130 -136 -153 -172 -278
Total Operating Income		 -24 -28 -63 -67 -92 -131 -140 -166 -193 -304
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 54 67
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 54 67
Operating Revenue		 - - - - - - 0.00 - 54 67
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06
Operating Cost of Revenue		 - - - - - - - - 0.00 0.06
Total Operating Expenses		 24 28 63 67 92 131 140 166 247 371
Selling, General & Admin Expense		 6.09 7.96 16 20 32 47 47 51 77 120
Research & Development Expense		 18 20 47 48 60 85 93 115 170 251
Total Other Income / (Expense), net		 1.24 0.81 2.44 4.34 2.27 0.79 4.03 13 21 25
Interest Expense		 0.09 0.58 1.47 0.58 0.58 0.41 0.23 1.55 1.62 1.51
Interest & Investment Income		 0.13 0.50 3.17 4.92 2.85 1.21 4.25 15 23 27
Income Tax Expense		 - - - - - - 0.00 0.00 2.02 0.30
Basic Earnings per Share		 ($2.28) ($1.47) ($1.72) ($1.51) ($1.69) ($1.97) ($2.03) ($2.08) ($2.02) ($3.18)
Weighted Average Basic Shares Outstanding		 9.93M 18.70M 35.19M 41.95M 53.08M 66.35M 66.99M 73.23M 86.16M 87.68M
Diluted Earnings per Share		 ($2.28) ($1.47) ($1.72) ($1.51) ($1.69) ($1.97) ($2.03) ($2.08) ($2.02) ($3.18)
Weighted Average Diluted Shares Outstanding		 9.93M 18.70M 35.19M 41.95M 53.08M 66.35M 66.99M 73.23M 86.16M 87.68M
Weighted Average Basic & Diluted Shares Outstanding		 9.93M 18.70M 35.19M 41.95M 53.08M 66.35M 68.44M 76.14M 80.75M 88.33M

Quarterly Income Statements for Kura Oncology

This table shows Kura Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -37 -44 -50 -51 -54 -21 -57 -66 -74 -81 -73
Consolidated Net Income / (Loss)		 -39 -43 -50 -51 -54 -19 -57 -66 -74 -81 -73
Net Income / (Loss) Continuing Operations		 -39 -43 -50 -51 -54 -19 -57 -66 -74 -81 -73
Total Pre-Tax Income 		-39 -43 -50 -51 -54 -17 -57 -66 -74 -81 -73
Total Operating Income		 -42 -47 -54 -56 -60 -22 -65 -73 -80 -86 -79
Total Gross Profit		 0.00 - 0.00 0.00 0.00 54 14 15 21 17 18
Total Revenue		 0.00 - 0.00 0.00 0.00 54 14 15 21 17 18
Operating Revenue		 - - 0.00 0.00 0.00 - 14 15 21 17 18
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.06 0.26
Operating Cost of Revenue		 - - - - - - 0.00 - - - 0.26
Total Operating Expenses		 42 47 54 56 60 76 79 88 101 104 97
Selling, General & Admin Expense		 13 14 18 17 18 24 23 25 33 39 32
Research & Development Expense		 29 33 36 40 42 52 56 63 68 64 65
Total Other Income / (Expense), net		 3.87 3.98 4.93 5.57 5.48 5.26 7.50 6.54 5.88 5.34 5.49
Interest Expense		 0.40 0.39 0.40 0.41 0.41 0.40 0.38 0.39 0.39 0.35 0.34
Interest & Investment Income		 4.28 4.37 5.33 5.97 5.89 5.66 7.88 6.94 6.27 5.69 5.83
Income Tax Expense		 - - 0.00 0.00 0.00 - 0.23 0.00 0.00 0.07 0.01
Basic Earnings per Share		 ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21) ($0.66) ($0.75) ($0.85) ($0.92) ($0.83)
Weighted Average Basic Shares Outstanding		 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M 87.42M 87.59M 87.65M 87.68M 88.61M
Diluted Earnings per Share		 ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21) ($0.66) ($0.75) ($0.85) ($0.92) ($0.83)
Weighted Average Diluted Shares Outstanding		 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M 87.42M 87.59M 87.65M 87.68M 88.61M
Weighted Average Basic & Diluted Shares Outstanding		 74.27M 76.14M 76.18M 76.63M 77.76M 80.75M 86.57M 86.80M 87.02M 88.33M 88.77M

Annual Cash Flow Statements for Kura Oncology

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 14 -5.72 4.69 10 300 -235 -39 -14 187 -75
Net Cash From Operating Activities		 -18 -25 -49 -55 -70 -105 -110 -125 134 -64
Net Cash From Continuing Operating Activities		 -18 -25 -49 -55 -70 -105 -110 -125 134 -64
Net Income / (Loss) Continuing Operations		 -23 -28 -60 -63 -90 -130 -136 -153 -174 -279
Consolidated Net Income / (Loss)		 -23 -28 -60 -63 -90 -130 -136 -153 -174 -279
Depreciation Expense		 0.02 0.03 0.00 0.00 0.19 0.56 0.76 0.85 0.85 1.03
Amortization Expense		 0.17 0.17 -1.75 -1.10 0.41 4.79 1.68 -8.94 -13 -7.97
Non-Cash Adjustments To Reconcile Net Income		 6.72 2.39 9.15 9.41 14 23 27 27 35 31
Changes in Operating Assets and Liabilities, net		 -2.21 -0.38 4.38 0.07 5.18 -2.90 -3.55 8.50 285 191
Net Cash From Investing Activities		 -71 12 -79 -46 -100 -127 33 16 -102 -13
Net Cash From Continuing Investing Activities		 -71 12 -79 -46 -100 -127 33 16 -102 -13
Purchase of Property, Plant & Equipment		 -0.06 - 0.00 0.00 -2.17 -1.15 -0.63 -0.17 -0.47 -6.64
Purchase of Investments		 -77 -56 -237 -228 -321 -446 -271 -410 -659 -762
Sale and/or Maturity of Investments		 6.00 69 158 181 223 320 304 426 558 755
Net Cash From Financing Activities		 103 7.45 133 111 469 -3.44 39 95 154 1.79
Net Cash From Continuing Financing Activities		 103 7.45 133 111 469 -3.44 39 95 154 1.79
Repayment of Debt		 - 0.00 -1.25 0.00 -0.25 -7.86 -0.58 0.00 0.00 0.00
Issuance of Debt		 5.00 7.45 0.63 - 0.00 0.00 10 0.00 0.00 0.00
Issuance of Common Equity		 98 0.00 132 108 470 4.43 29 95 154 1.79
Cash Interest Paid		 0.00 0.35 0.64 0.43 0.42 0.78 0.07 1.06 1.10 1.00

Quarterly Cash Flow Statements for Kura Oncology

This table details how cash moves in and out of Kura Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -20 8.58 4.19 3.68 4.30 175 -173 31 13 54 -110
Net Cash From Operating Activities		 -29 -34 -49 -43 -43 269 -72 -29 -81 117 -86
Net Cash From Continuing Operating Activities		 -29 -34 -49 -43 -43 269 -72 -29 -81 117 -86
Net Income / (Loss) Continuing Operations		 -39 -43 -50 -51 -54 -19 -57 -66 -74 -81 -73
Consolidated Net Income / (Loss)		 -39 -43 -50 -51 -54 -19 -57 -66 -74 -81 -73
Depreciation Expense		 0.22 0.21 0.23 0.20 0.21 0.20 0.24 0.22 0.16 0.40 0.36
Amortization Expense		 -2.77 -2.61 -3.15 -3.42 -3.30 -2.75 -2.53 -2.38 -1.78 -1.28 -0.79
Non-Cash Adjustments To Reconcile Net Income		 7.37 5.70 8.74 8.97 7.82 9.32 41 -29 8.08 11 3.44
Changes in Operating Assets and Liabilities, net		 4.76 5.17 -5.15 2.56 6.24 282 -53 68 -13 188 -16
Net Cash From Investing Activities		 8.56 42 -95 43 46 -95 -101 59 94 -65 -24
Net Cash From Continuing Investing Activities		 8.56 42 -95 43 46 -95 -101 59 94 -65 -24
Purchase of Property, Plant & Equipment		 -0.02 -0.02 -0.08 -0.02 - -0.37 -0.29 -1.46 -2.57 -2.32 -0.13
Purchase of Investments		 -97 -100 -195 -162 -62 -241 -269 -115 -138 -240 -172
Sale and/or Maturity of Investments		 105 142 100 205 107 146 168 175 235 178 147
Net Cash From Financing Activities		 0.08 0.69 148 3.04 2.20 0.81 0.14 0.52 - 1.14 0.07
Net Cash From Continuing Financing Activities		 0.08 0.69 148 3.04 2.20 0.81 0.14 0.52 - 1.14 0.07
Issuance of Common Equity		 0.08 0.69 148 3.04 2.20 0.81 0.14 0.52 - 1.14 0.07

Annual Balance Sheets for Kura Oncology

This table presents Kura Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 1.38 87 70 96 242 647 534 456 449 760 738
Total Current Assets		 1.20 87 69 95 240 637 522 446 432 745 709
Cash & Equivalents		 1.12 15 9.73 11 26 325 91 52 37 224 149
Short-Term Investments		 - 70 58 82 211 308 427 386 387 503 518
Accounts Receivable		 0.03 0.43 0.30 0.22 - - - - - 2.06 8.80
Inventories, net		 - - - - - - - - - 0.00 0.41
Prepaid Expenses		 0.04 0.69 0.73 1.28 2.71 3.97 4.33 8.44 8.52 15 32
Plant, Property, & Equipment, net		 0.03 0.07 0.04 0.01 0.04 2.02 2.67 2.54 1.86 1.68 7.86
Total Noncurrent Assets		 0.16 0.32 0.97 1.20 2.33 7.90 9.09 7.34 15 14 22
Other Noncurrent Operating Assets		 0.16 0.32 0.97 1.20 2.33 7.90 9.09 7.34 15 14 22
Total Liabilities & Shareholders' Equity		 1.38 87 70 96 242 647 534 456 449 760 738
Total Liabilities		 4.81 5.16 13 16 23 36 27 36 52 347 564
Total Current Liabilities		 3.02 5.06 5.45 10 16 26 22 24 35 79 117
Short-Term Debt		 2.04 - 0.00 1.53 0.25 3.00 - - 0.00 2.61 0.00
Accounts Payable		 0.98 5.06 5.45 8.50 15 23 20 22 34 1.47 5.02
Accrued Expenses		 - - - - - - - - - 48 62
Current Deferred Revenue		 - - - - - - - - 0.00 24 49
Other Current Liabilities		 - - - - - - 2.26 2.32 1.51 1.88 1.28
Total Noncurrent Liabilities		 1.80 0.10 7.49 5.96 7.63 10 4.99 12 16 268 447
Long-Term Debt		 0.49 0.00 7.32 5.57 7.25 4.25 0.00 9.16 9.33 6.92 9.71
Noncurrent Deferred Revenue		 - - - - - - - - 0.00 254 425
Other Noncurrent Operating Liabilities		 1.30 0.10 0.17 0.39 0.38 6.03 4.99 2.81 7.07 6.99 13
Total Equity & Noncontrolling Interests		 -3.43 82 57 80 219 611 507 420 397 414 174
Total Preferred & Common Equity		 -3.43 82 57 80 219 611 507 420 397 414 174
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -3.43 82 57 80 219 611 507 420 397 414 174
Common Stock		 0.24 108 111 169 431 913 941 997 1,120 1,308 1,347
Retained Earnings		 -3.67 -26 -54 -89 -213 -303 -433 -569 -721 -895 -1,174
Accumulated Other Comprehensive Income / (Loss)		 - -0.09 -0.02 -0.05 0.33 0.05 -1.79 -8.03 -1.27 0.76 1.02

Quarterly Balance Sheets for Kura Oncology

This table presents Kura Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 448 426 495 474 554 515 479 744 682 649 653
Total Current Assets		 436 416 486 460 538 500 463 724 660 621 624
Cash & Equivalents		 91 27 49 29 42 45 49 51 82 95 39
Short-Term Investments		 337 379 428 424 486 446 406 607 549 454 542
Accounts Receivable		 - - - - - - - 49 4.57 36 9.35
Inventories, net		 - - - - - - - - - - 0.84
Prepaid Expenses		 8.62 11 8.67 7.32 11 8.25 7.89 17 25 35 33
Plant, Property, & Equipment, net		 2.73 2.37 2.25 2.06 1.71 1.52 1.32 2.35 3.91 7.40 7.61
Total Noncurrent Assets		 8.86 7.16 6.84 12 14 14 14 17 18 21 21
Other Noncurrent Operating Assets		 8.86 7.16 6.84 12 14 14 14 17 18 21 21
Total Liabilities & Shareholders' Equity		 448 426 495 474 554 515 479 744 682 649 653
Total Liabilities		 28 31 35 44 49 49 55 379 377 407 545
Total Current Liabilities		 25 19 24 28 32 33 40 90 107 121 101
Short-Term Debt		 - - - - - 0.85 1.72 1.92 3.11 4.34 0.00
Accounts Payable		 22 17 22 26 31 31 37 45 53 67 7.04
Accrued Expenses		 - - - - - - - - - - 45
Current Deferred Revenue		 - - - - - - - 41 49 49 48
Other Current Liabilities		 2.30 2.33 2.35 1.68 1.36 1.47 1.69 1.91 1.70 1.43 1.28
Total Noncurrent Liabilities		 3.62 12 11 16 17 16 15 290 270 286 443
Long-Term Debt		 - 9.20 9.24 9.29 9.38 8.58 7.76 7.65 6.51 5.34 9.75
Noncurrent Deferred Revenue		 - - - - - - - 272 253 269 417
Other Noncurrent Operating Liabilities		 3.62 2.36 1.92 7.02 7.18 7.02 6.94 10 11 11 17
Total Equity & Noncontrolling Interests		 420 395 460 430 505 466 424 364 305 243 108
Total Preferred & Common Equity		 420 395 460 430 505 466 424 364 305 243 108
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 420 395 460 430 505 466 424 364 305 243 108
Common Stock		 965 1,004 1,105 1,112 1,277 1,288 1,299 1,316 1,324 1,335 1,356
Retained Earnings		 -536 -603 -640 -679 -771 -822 -876 -953 -1,019 -1,093 -1,247
Accumulated Other Comprehensive Income / (Loss)		 -9.42 -5.90 -5.22 -3.54 -0.82 -0.46 1.12 0.97 0.71 0.92 -0.38

Annual Metrics And Ratios for Kura Oncology

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 21,370,560.00 21,367,747.00 30,215,556.00 38,036,952.00 45,314,684.00 56,708,089.00 66,555,775.00 - - - 87,017,518.00
DEI Adjusted Shares Outstanding		 21,370,560.00 21,367,747.00 30,215,556.00 38,036,952.00 45,314,684.00 56,708,089.00 66,555,775.00 - - - 87,017,518.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.06 -1.29 - -1.59 -1.39 -1.58 -1.96 - - - -3.20
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -17 -20 -36 -44 -47 -64 -92 -98 -116 -135 -213
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -22.80% -28.54% -31.96% -115.61%
Earnings before Interest and Taxes (EBIT)		 -23 -27 -35 -62 -67 -92 -131 -140 -166 -193 -304
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -22 -27 -35 -64 -69 -91 -126 -137 -174 -205 -311
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -20 -33 -50 -37 -60 -96 -101 -107 152 -33
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.64 -3.59 -6.18 0.00 -11 -15 -11 -8.55 -17 -304 -483
Increase / (Decrease) in Invested Capital		 0.00 0.05 -2.59 6.18 -11 -4.56 3.81 2.80 -8.80 -287 -179
Book Value per Share		 $3.84 $2.66 $2.39 $0.00 $4.83 $10.77 $7.61 $6.28 $5.35 $5.32 $2.00
Tangible Book Value per Share		 $3.84 $2.66 $2.39 $0.00 $4.83 $10.77 $7.61 $6.28 $5.35 $5.32 $2.00
Total Capital		 82 64 87 0.00 226 618 507 429 407 423 184
Total Debt		 0.00 7.32 7.10 0.00 7.50 7.25 0.00 9.16 9.33 9.52 9.71
Total Long-Term Debt		 0.00 7.32 5.57 0.00 7.25 4.25 0.00 9.16 9.33 6.92 9.71
Net Debt		 -86 -60 -86 0.00 -229 -626 -518 -429 -415 -718 -658
Capital Expenditures (CapEx)		 0.06 0.00 0.00 0.00 0.00 2.17 1.15 0.63 0.17 0.47 6.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.93 -4.43 -7.00 0.00 -13 -19 -18 -16 -27 -59 -76
Debt-free Net Working Capital (DFNWC)		 82 63 86 0.00 224 614 500 422 397 669 592
Net Working Capital (NWC)		 82 63 85 0.00 224 611 500 422 397 666 592
Net Nonoperating Expense (NNE)		 5.92 7.70 -0.64 16 16 25 39 38 37 39 66
Net Nonoperating Obligations (NNO)		 -86 -60 -86 0.00 -229 -626 -518 -429 -415 -718 -658
Total Depreciation and Amortization (D&A)		 0.19 0.20 -0.11 -1.75 -1.10 0.60 5.35 2.44 -8.09 -12 -6.94
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.28) ($1.47) ($1.52) ($1.72) $0.00 ($1.69) ($1.97) ($2.03) ($2.08) ($2.02) ($3.18)
Adjusted Weighted Average Basic Shares Outstanding		 21.37M 21.38M 23.30M 38.17M 0.00 66.21M 66.61M 66.99M 73.23M 86.16M 87.68M
Adjusted Diluted Earnings per Share		 ($2.28) ($1.47) ($1.52) ($1.72) $0.00 ($1.69) ($1.97) ($2.03) ($2.08) ($2.02) ($3.18)
Adjusted Weighted Average Diluted Shares Outstanding		 21.37M 21.38M 33.35M 38.17M 0.00 66.21M 66.61M 66.99M 73.23M 86.16M 87.68M
Adjusted Basic & Diluted Earnings per Share		 ($2.28) ($1.47) ($1.52) ($1.72) $0.00 ($1.69) ($1.97) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 9.93M 18.70M 23.24M 35.19M 0.00 53.08M 66.35M 68.44M 76.14M 80.75M 88.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -20 -25 -44 -47 -64 -92 -98 -116 -135 -213
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Kura Oncology

This table displays calculated financial ratios and metrics derived from Kura Oncology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 80,754,961.00 86,574,687.00 86,797,185.00 87,017,518.00 88,329,759.00
DEI Adjusted Shares Outstanding		 - - - - - - 80,754,961.00 86,574,687.00 86,797,185.00 87,017,518.00 88,329,759.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -0.71 -0.76 -0.85 -0.93 -0.83
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 29.47%
EBITDA Growth		 -24.96% -38.36% -51.23% -42.71% -39.88% 49.16% -16.77% -25.49% -29.59% - -18.31%
EBIT Growth		 -16.07% -33.01% -48.91% -41.00% -40.99% 51.98% -18.82% -28.83% -33.59% - -21.82%
NOPAT Growth		 -16.07% -33.01% -48.91% -41.00% -40.99% 51.98% -18.82% -28.83% -33.59% - -21.82%
Net Income Growth		 -8.73% -29.21% -45.37% -36.75% -40.94% 55.09% -15.96% -30.07% -36.23% - -27.69%
EPS Growth		 5.66% -12.24% -18.00% -11.32% -26.00% 61.82% -11.86% -27.12% -34.92% - -25.76%
Operating Cash Flow Growth		 -38.16% -29.32% -36.16% -66.02% -49.65% 884.46% -47.26% 32.34% -85.61% - -19.36%
Free Cash Flow Firm Growth		 9.70% 12.70% 3.34% -52.15% -35.54% 1,233.13% 938.90% 889.27% 760.21% - -45.28%
Invested Capital Growth		 -63.93% -102.97% -734.67% -98.91% -64.99% -1,653.30% -2,144.62% -1,869.43% -1,248.73% - -62.97%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -73.82% 8.36% 35.73% - 5.36%
EBITDA Q/Q Growth		 -7.77% -9.19% -16.69% -3.94% -5.63% 60.31% -167.99% -11.70% -9.08% - 9.05%
EBIT Q/Q Growth		 -6.17% -10.10% -16.45% -3.58% -6.17% 62.50% -188.13% -12.31% -10.09% - 8.64%
NOPAT Q/Q Growth		 -6.17% -10.10% -16.45% -3.58% -6.17% 62.50% -188.13% -12.31% -10.09% - 8.64%
Net Income Q/Q Growth		 -3.84% -10.84% -15.75% -2.65% -7.02% 64.68% -198.84% -15.14% -12.09% - 9.46%
EPS Q/Q Growth		 5.66% -10.00% -7.27% 0.00% -6.78% 66.67% -214.29% -13.64% -13.33% - 9.78%
Operating Cash Flow Q/Q Growth		 -13.31% -18.19% -42.37% 12.93% -2.14% 719.55% -126.73% 59.99% -180.18% - -173.21%
Free Cash Flow Firm Q/Q Growth		 -18.38% 2.40% -12.71% -16.84% -5.45% 915.97% -16.56% 9.93% -11.79% - 4.24%
Invested Capital Q/Q Growth		 -65.91% -29.81% 27.03% -26.57% -37.61% -1,279.49% 6.58% -11.05% 5.76% - 4.18%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% - 98.57%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -46.39% -474.82% -489.43% -393.33% - -433.91%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -41.67% -458.61% -475.31% -385.53% - -431.51%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -41.67% -458.61% -475.31% -385.53% - -431.51%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -35.66% -407.07% -432.51% -357.19% - -401.49%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 111.73% 100.40% 100.00% 100.00% - 100.01%
Interest Burden Percent		 90.89% 91.50% 90.95% 90.13% 90.85% 76.59% 88.41% 90.99% 92.65% - 93.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -33.65% -37.34% -37.34% -39.27% -46.28% -42.91% -41.84% -51.11% -65.10% - -124.74%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -3.71% -48.06% -66.11% -71.10% - -44.28%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -3.18% -42.66% -60.15% -65.87% - -41.20%
Return on Common Equity (ROCE)		 -33.65% -37.34% -37.34% -39.27% -46.28% -42.91% -41.84% -51.11% -65.10% - -124.74%
Return on Equity Simple (ROE_SIMPLE)		 -33.25% 0.00% -33.28% -39.00% -46.62% 0.00% -49.91% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -30 -33 -38 -39 -42 -16 -45 -51 -56 -60 -55
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -29.17% -321.02% -332.72% -269.87% - -302.06%
Net Nonoperating Expense Percent (NNEP)		 -2.04% -2.38% -2.50% -2.39% -2.81% -0.62% -2.08% -2.77% -3.68% - -2.98%
Return On Investment Capital (ROIC_SIMPLE)		 - -8.05% - - - -3.71% -12.11% -16.14% -22.20% -32.85% -46.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 1.43%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 44.67% 161.86% 164.63% 158.26% - 172.76%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 97.00% 396.75% 410.68% 327.27% - 357.31%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 141.67% 558.61% 575.31% 485.53% - 530.07%
Earnings before Interest and Taxes (EBIT)		 -42 -47 -54 -56 -60 -22 -65 -73 -80 -86 -79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -49 -57 -60 -63 -25 -67 -75 -82 -87 -79
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.57 2.69 3.14 3.37 3.53 1.64 1.46 1.64 3.17 - 6.66
Price to Tangible Book Value (P/TBV)		 1.57 2.69 3.14 3.37 3.53 1.64 1.46 1.64 3.17 - 6.66
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 12.57 7.84 6.00 7.38 - 10.02
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.19 - 2.05
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.60 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.12 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.04 - 0.09
Long-Term Debt to Equity		 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 - 0.09
Financial Leverage		 -1.03 -1.03 -1.02 -1.03 -1.04 -1.40 -1.34 -1.43 -1.48 - -2.58
Leverage Ratio		 1.09 1.11 1.09 1.09 1.12 1.49 1.49 1.55 1.69 - 2.96
Compound Leverage Factor		 0.99 1.01 0.99 0.98 1.01 1.14 1.32 1.41 1.57 - 2.75
Debt to Total Capital		 2.11% 2.30% 1.82% 1.98% 2.19% 2.25% 2.56% 3.05% 3.84% - 8.29%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.18% 0.40% 0.62% 0.51% 0.99% 1.72% - 0.00%
Long-Term Debt to Total Capital		 2.11% 2.30% 1.82% 1.80% 1.79% 1.63% 2.05% 2.07% 2.12% - 8.29%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 97.89% 97.70% 98.18% 98.02% 97.81% 97.75% 97.44% 96.95% 96.16% - 91.71%
Debt to EBITDA		 -0.06 -0.05 -0.05 -0.04 -0.04 -0.05 -0.04 -0.04 -0.04 - -0.03
Net Debt to EBITDA		 2.77 2.38 2.68 2.28 1.95 3.50 3.02 2.70 2.17 - 1.77
Long-Term Debt to EBITDA		 -0.06 -0.05 -0.05 -0.04 -0.03 -0.03 -0.04 -0.03 -0.02 - -0.03
Debt to NOPAT		 -0.09 -0.08 -0.07 -0.07 -0.06 -0.07 -0.07 -0.06 -0.06 - -0.04
Net Debt to NOPAT		 4.11 3.57 4.03 3.44 2.93 5.31 4.55 4.04 3.22 - 2.57
Long-Term Debt to NOPAT		 -0.09 -0.08 -0.07 -0.06 -0.05 -0.05 -0.05 -0.04 -0.03 - -0.04
Altman Z-Score		 8.06 10.87 18.29 17.68 14.40 0.55 -0.12 -0.55 -0.55 - -1.21
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.71 12.26 16.67 14.94 11.47 9.46 8.07 6.16 5.12 - 6.15
Quick Ratio		 16.44 12.02 16.34 14.69 11.28 9.24 7.88 5.93 4.83 - 5.81
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 -24 -27 -32 -33 271 226 249 219 119 124
Operating Cash Flow to CapEx		 -145,135.00% -214,425.00% -58,147.62% -265,812.50% 0.00% 72,347.04% -24,632.53% -1,973.73% -3,140.90% - -67,073.44%
Free Cash Flow to Firm to Interest Expense		 -60.69 -60.74 -67.77 -77.62 -80.66 672.86 592.31 636.14 558.26 - 368.47
Operating Cash Flow to Interest Expense		 -71.85 -87.08 -122.72 -104.75 -105.44 667.82 -188.29 -73.60 -205.16 - -255.52
Operating Cash Flow Less CapEx to Interest Expense		 -71.90 -87.12 -122.93 -104.79 -105.44 666.90 -189.06 -77.33 -211.69 - -255.90
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.09 0.10 0.14 0.18 - 0.10
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 2.47
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 30.43 33.52 30.65 23.88 - 14.38
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.01
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 147.99
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 29,827.59
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -29,679.60
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -13 -17 -13 -16 -22 -304 -284 -316 -297 -483 -463
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -0.34 -0.46 -0.50 -0.65 - -0.19
Increase / (Decrease) in Invested Capital		 -5.21 -8.80 -11 -7.97 -8.69 -287 -272 -300 -275 -179 -179
Enterprise Value (EV)		 234 653 1,066 1,086 1,052 -41 -116 -122 228 - 147
Market Capitalization		 677 1,068 1,584 1,569 1,497 677 533 500 768 - 718
Book Value per Share		 $5.79 $5.35 $6.02 $6.12 $5.53 $5.32 $4.51 $3.53 $2.79 $2.00 $1.22
Tangible Book Value per Share		 $5.79 $5.35 $6.02 $6.12 $5.53 $5.32 $4.51 $3.53 $2.79 $2.00 $1.22
Total Capital		 439 407 514 475 433 423 374 315 252 184 118
Total Debt		 9.29 9.33 9.38 9.42 9.47 9.52 9.57 9.62 9.67 9.71 9.75
Total Long-Term Debt		 9.29 9.33 9.38 8.58 7.76 6.92 7.65 6.51 5.34 9.71 9.75
Net Debt		 -443 -415 -518 -482 -446 -718 -649 -621 -540 -658 -571
Capital Expenditures (CapEx)		 0.02 0.02 0.08 0.02 0.00 0.37 0.29 1.46 2.57 2.32 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -27 -22 -24 -31 -59 -22 -75 -46 -76 -59
Debt-free Net Working Capital (DFNWC)		 432 397 506 467 425 669 636 556 504 592 522
Net Working Capital (NWC)		 432 397 506 466 423 666 634 553 499 592 522
Net Nonoperating Expense (NNE)		 8.87 10 11 11 12 3.50 12 15 18 21 18
Net Nonoperating Obligations (NNO)		 -443 -415 -518 -482 -446 -718 -649 -621 -540 -658 -571
Total Depreciation and Amortization (D&A)		 -2.55 -2.40 -2.91 -3.22 -3.10 -2.54 -2.29 -2.16 -1.62 -0.88 -0.44
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -108.89% -32.12% -89.72% -44.19% - -81.71%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,241.07% 935.94% 667.65% 484.19% - 729.05%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 1,236.23% 933.11% 663.91% 480.02% - 729.05%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21) ($0.66) ($0.75) ($0.85) ($0.92) ($0.83)
Adjusted Weighted Average Basic Shares Outstanding		 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M 87.42M 87.59M 87.65M 87.68M 88.61M
Adjusted Diluted Earnings per Share		 ($0.50) ($0.55) ($0.59) ($0.59) ($0.63) ($0.21) ($0.66) ($0.75) ($0.85) ($0.92) ($0.83)
Adjusted Weighted Average Diluted Shares Outstanding		 77.24M 73.23M 83.91M 86.64M 86.95M 86.16M 87.42M 87.59M 87.65M 87.68M 88.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 74.27M 76.14M 76.18M 76.63M 77.76M 80.75M 86.57M 86.80M 87.02M 88.33M 88.77M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -33 -38 -39 -42 -16 -45 -51 -56 -60 -55
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -29.17% -321.02% -332.72% -269.87% - -302.06%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -31.92% -405.47% -432.51% -357.19% - -401.45%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -105.13 -118.69 -136.81 -138.93 -145.35 -55.72 -169.37 -185.85 -203.55 - -234.57
NOPAT to Interest Expense		 -73.59 -83.08 -95.77 -97.25 -101.74 -39.00 -118.56 -130.09 -142.49 - -164.20
EBIT Less CapEx to Interest Expense		 -105.18 -118.73 -137.03 -138.97 -145.35 -56.64 -170.14 -189.58 -210.09 - -234.95
NOPAT Less CapEx to Interest Expense		 -73.64 -83.12 -95.98 -97.29 -101.74 -39.93 -119.32 -133.82 -149.02 - -164.58
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Kura Oncology (NASDAQ: KURA) has generated a multi-year history of growing R&D spend and net losses, but its liquidity has shown episodic improvement driven by equity raises and investment activities. Below are the key trends from the last four years, focused on quarterly cash flow, income statement, and balance sheet data.

  • Capital raises have provided liquidity across multiple periods. The company has periodically issued common equity, delivering meaningful cash infusions (e.g., Q4 2024 roughly $25.3M; smaller but recurring equity issuances in earlier quarters).
  • Significant cash inflows from the sale/maturity of investments have bolstered liquidity in several quarters. Examples include Q3 2025 about $235.0M, Q4 2024 about $141.9M, and Q4 2025 about $177.5M from investments; these inflows helped offset other uses of cash in those periods.
  • Ending cash balances trended higher through 2025, suggesting improving near-term liquidity. Quarter-end cash on the balance sheet rose from roughly $51M (Q1 2025) to about $95M (Q3 2025), indicating better cash availability at times in 2025.
  • Total assets remained sizable across 2025, providing a liquidity cushion. Balance sheets show total assets generally in the hundreds of millions (e.g., mid- to upper-$600Ms to mid-$700Ms range in 2025), offering collateral and financing options, despite other headwinds.
  • Financing activities occasionally produced net cash inflows, reflecting the company’s ability to obtain external funds. Periods with positive net cash from financing activities contributed to overall liquidity, even as operating activities remained uncertain.
  • Revenue volatility remains pronounced. Total revenue in 2025 Q4 was about $17.3M vs roughly $53.9M in 2024 Q4, signaling a volatile revenue base tied to clinical and product-cycle timing rather than steady recurring revenue.
  • Operating losses persist with higher operating expenses in 2025. 2025 Q4 shows total operating expenses around $103.5M, driven by SG&A and substantial R&D spend, leading to a negative operating income.
  • Equity dilution appears ongoing, but has supported balance sheet liquidity. Ongoing equity issuances help fund operations but raise dilution concerns for existing shareholders.
  • Retained earnings (accumulated deficit) are very large and negative. Retained earnings stand around -$1.0B at times in 2024–2025, reflecting a long-running deficit that worsened in 2025.
  • Cash flow from operating activities is typically negative, highlighting dependence on external financing. Periods like 2025 Q3 (-$80.6M) and Q2 2025 (-$28.8M) show ongoing cash burn from core operations.
  • Liabilities have exceeded equity in several quarters, indicating leverage and balance-sheet fragility. For example, in 2025 Q3 Total Liabilities (~$406.8M) exceeded Total Equity (~$242.5M), underscoring a leveraged position and resilience risk.
  • Consistent net losses and negative EPS across quarters (e.g., 2025 Q4 net income around -$81.0M, EPS about -$0.92) illustrate ongoing profitability challenges, despite any liquidity-supportive financing activity.

In short, Kura’s four-year trend is characterized by a challenging operating backdrop (sustained losses, high R&D spend, and cash burn) but with episodic liquidity improvements driven by equity issuances and investment activity. Retail investors should weigh the company’s ability to raise capital and monetize investments against the persistent profitability and leverage risks reflected in the income statements and balance sheets.

05/18/26 07:20 AM ETAI Generated. May Contain Errors.

Kura Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Kura Oncology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Kura Oncology's net income appears to be on an upward trend, with a most recent value of -$278.67 million in 2025, rising from -$22.63 million in 2015. The previous period was -$173.98 million in 2024. See where experts think Kura Oncology is headed by visiting Kura Oncology's forecast page.

Kura Oncology's total operating income in 2025 was -$303.63 million, based on the following breakdown:
  • Total Gross Profit: $67.43 million
  • Total Operating Expenses: $371.06 million

Over the last 9 years, Kura Oncology's total revenue changed from $0.00 in 2015 to $67.48 million in 2025, a change of 6,748,200,000.0%.

Kura Oncology's total liabilities were at $564.23 million at the end of 2025, a 62.8% increase from 2024, and a 11,627.9% increase since 2014.

In the past 10 years, Kura Oncology's cash and equivalents has ranged from $1.12 million in 2014 to $325.49 million in 2020, and is currently $149.10 million as of their latest financial filing in 2025.

Over the last 10 years, Kura Oncology's book value per share changed from 3.84 in 2015 to 2.00 in 2025, a change of -47.9%.


Related Companies

Financial statements for NASDAQ:KURA last updated on 5/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Distracted Americans set to miss out on quadrillions
Technology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
The filing was one thing. June 1 is another.
The SpaceX filing got attention - but according to macroeconomic strategist Dr. Mark Skousen of The Oxford Clu...
The Oxford Club | Sponsoredtc pixel